bcv Brincidofovir treatment efficacy in two well characterized orthopoxvirus infection models of smallpox ASM Biothreats 2020 Grossi IM, Sanford CD, Gainey MR, et al.
bcv Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits Antiviral Res 2017 Grossi IM, Foster SA, Gainey MR, et al.
bcv Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies Ther Drug Monit. 2016 Tippin TK, Morrison ME, Brundage TM, Momméja-Marin H.
bcv The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease. Antiviral Res 2015 Trost LC, Rose ML, Khouri J, et al.
bcv Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus Antiviral Res. 2014 Parker S, Crump R, Foster S, et al.
bcv In vitro efficacy of brincidofovir against variola virus Antimicrob Agents Chemother 2014 Olson VA, Smith SK, Foster S, Li Y, et al.
bcv Development of CMX001 for the treatment of poxvirus infections Viruses 2010 Lanier R, Trost L, Tippin T,et al.
bcv Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity Antiviral Res. 2009 Hostetler KY.
bcv Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses Antimicrob.Agents Chemother. 2007 Quenelle DC, Prichard MN, Keith KA, et al.
bcv Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox Journal of Virology 2007 Adams MA, Rice AD, Moyer RW.